PAIR Technology | Chronic Inflammation | Metabolic Health
HUNTINGTON, N.Y., Jan. 13, 2025 /PRNewswire/ — Sen-Jam Pharmaceutical is proud to announce a pivotal moment in its mission to transform the way the world heals by tackling inflammation at its source. With our groundbreaking PAIR (Pleiotropic Anti-Inflammatory Remedies) technology, we are developing novel therapeutics that address acute, chronic, and systemic inflammatory conditions across a wide spectrum of health challenges, including metabolic disorders, obesity, acute infections, and low-grade chronic inflammation associated with aging.
Our proprietary PAIR technology is designed to address inflammation further upstream, reducing the cascade of damage before it begins. By targeting inflammation at its source through dual mechanisms of action, Sen-Jam’s approach preserves tissue integrity, protects healthspan, and supports the body’s innate healing capabilities. This pioneering strategy represents a paradigm shift in inflammatory care, paving the way for a future where vitality is preserved and disease progression is mitigated.
Sen-Jam’s innovative pipeline is aimed at resolving diverse inflammatory conditions:
“Sen-Jam is not just developing therapies; we’re rewriting the playbook on how we approach inflammation and healing,” said Neal Zahn, Director of Global Licensing. “By addressing inflammation upstream, we’re creating solutions that preserve healthspan and empower the body’s natural defenses to thrive. This is the future of medicine.“
Jackie Iversen RPh MS, Co-Founder and Chief Clinical Officer, adds, “Our pipeline represents more than just innovation—it’s a commitment to challenging the status quo and delivering real, lasting impact for patients worldwide.”
Sen-Jam’s leadership team is in San Francisco this week for the prestigious JPMorgan Healthcare Conference. We invite interested parties to reach out to learn more about our vision, pipeline, and partnership opportunities. Let’s connect and shape the future of healthcare together. To learn more visit wefunder.com/senjam.
Sen-Jam Pharmaceutical (“Sen-Jam”) is pioneering a revolutionary approach to addressing chronic inflammation and metabolic disorders, including obesity, with our proprietary “Pleiotropic Anti-Inflammatory Remedies” (or “PAIR”) technology. By working in harmony with the body’s innate immune system, our precision remedies target inflammation at its source, mitigating systemic risks associated with chronic conditions without suppressing the immune response. Sen-Jam is at the forefront of the next evolution in healthcare, delivering innovative treatments that enhance metabolic health, promote vitality, extend health spans, and redefine how the world heals.
